TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Firebrick Pharma Limited ( (AU:FRE) ) has provided an update.
Firebrick Pharma Limited held its Annual General Meeting where all resolutions, including the special resolution for the approval of the 7.1A Mandate, were passed. This successful meeting indicates strong shareholder support and positions the company for continued growth and expansion in its market, potentially benefiting stakeholders through enhanced market presence and product offerings.
More about Firebrick Pharma Limited
Firebrick Pharma is a pharmaceutical innovator focused on developing and commercializing novel formulations and uses of povidone-iodine (PVP-I). The company has introduced Nasodine® Nasal Spray in markets such as the United States, Singapore, and Fiji & South Pacific, with plans for expansion into the Philippines. Additionally, Firebrick is preparing to launch its new product, Nasodine Throat Spray, in Singapore.
Average Trading Volume: 84,699
Technical Sentiment Signal: Sell
Current Market Cap: A$15.85M
Find detailed analytics on FRE stock on TipRanks’ Stock Analysis page.